Skip to main content
. Author manuscript; available in PMC: 2010 Nov 18.
Published in final edited form as: Cancer Res. 2008 Dec 15;68(24):10034–10039. doi: 10.1158/0008-5472.CAN-08-1687

Figure 1.

Figure 1

In vitro cell viability analysis of GBM xenograft explant cultures subjected to TMZ +/− p53 inhibitor treatments. A) GBM 26 cells were treated with TMZ only (black) at the indicated concentrations, or with TMZ + 10 μM cyclic pifithrin-α p-nitro (gray). Treatments were administered 1x/day for three consecutive days (each treatment group consisting of triplicate samples), and 4 days following final treatment the luminescence of each treatment group (Figure 1B) was determined. Average values for each treatment group are shown, with standard error of mean indicated. Asterisks denote comparisons for which there is a significant difference (p < 0.05) between TMZ only vs. TMZ + p53 inhibitor treatments. C) The same experimental design as described for GBM 26 was used for assessing p53null GBM 12 cell response to treatments, with results presented as indicated for panel A. D) Immunoblot results for p21 expression in cells treated with TMZ +/− p53 inhibitor (p53i). TMZ (100 μM) induces p21 expression in cells with wild-type p53 (GBM 26), and this induction is suppressed through concurrent treatment with p53 inhibitor (incubations as described above for panels A and C). In contrast to the results for GBM 26, p21 is not detected in p53null GBM 12 cells, irrespective of treatment (shown) or lack of treatment with TMZ. Replicate samples for this analysis yielded similar results.